<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="sc349@drexel.edu. *For P.Z.: phone, 086-531-88382005; email zhanpeng1982@sdu.edu.cn. epub: 2020-06-06acs.jmedchem.0c00502received: 2020-03-26(C)" exact="American" post="Chemical Society, 2020This article is made available via the"/>
 <result pre="to its virulence. SARS-CoV-2 is the etiological agent of â€œcoronavirus" exact="disease" post="2019â€�, abbreviated to COVID-19, which despite only being identified"/>
 <result pre="specific prophylactic or postexposure therapy for COVID-19 are currently available." exact="Viral" post="entry is the first step in the SARS-CoV-2 lifecycle"/>
 <result pre="coronaviruses, the lifecycle can be dissected into four steps, including" exact="viral" post="entry, replication, assembly, and release.2 Until last year, six"/>
 <result pre="are CoV-NL63, CoV-OC43, CoV-HKU1, and CoV-229E that could cause mild" exact="respiratory" post="tract diseases.3 However, two of the Î²-CoVs, the severe"/>
 <result pre="respiratory tract diseases.3 However, two of the Î²-CoVs, the severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV), and the Middle East respiratory"/>
 <result pre="tract diseases.3 However, two of the Î²-CoVs, the severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV), and the Middle East respiratory syndrome"/>
 <result pre="diseases.3 However, two of the Î²-CoVs, the severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV), and the Middle East respiratory syndrome coronavirus"/>
 <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV), and the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) have caused severe epidemics in the"/>
 <result pre="acute respiratory syndrome coronavirus (SARS-CoV), and the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) have caused severe epidemics in the past.4,5"/>
 <result pre="Figure 1 Countries with reported SARS-CoV-2 infections.10 Countries with reported" exact="infections" post="in blue and countries/areas with no reported infections in"/>
 <result pre="with reported infections in blue and countries/areas with no reported" exact="infections" post="in yellow (North Korea, Turkmenistan, and Western Sahara). Recently"/>
 <result pre="glycoprotein or S protein is responsible for receptor recognition and" exact="viral" post="entry into host cells. The spike protein can be"/>
 <result pre="host cell receptor, and S2 mediates membrane fusion (Figure 2).12" exact="Structural" post="alignment of SARS-CoV-2 S protein with SARS-CoV S protein"/>
 <result pre="1/2; TM, transmembrane domain S1/S2; S2â€²: protease cleavage sites. (C)" exact="Structural" post="alignment of SARS-CoV-2 S (in orange and HR1 in"/>
 <result pre="Engagement of the host cell receptor ACE2 is important for" exact="viral" post="entry; however, subsequent entry steps can vary and are"/>
 <result pre="place that cleaves and activates the S protein, therefore initiating" exact="viral" post="fusion with the endosomal/lysosomal membrane (Figure 3). In the"/>
 <result pre="suggesting substantial maturation requirements.15 In accordance with findings that mouse" exact="hepatitis" post="coronavirus (MHV) and feline coronavirus (FCV) infections of HeLa"/>
 <result pre="findings that mouse hepatitis coronavirus (MHV) and feline coronavirus (FCV)" exact="infections" post="of HeLa cells are also heavily dependent on endosomal"/>
 <result pre="viruses such as Ebola virus and Marburg virus, human immune" exact="deficiency" post="virus (HIV), and flaviviruses.22 To activate the S protein"/>
 <result pre="six-helix bundle (6-HB), a common postfusion structure shared by all" exact="type I" post="viral glycoproteins, to bring viral and cellular membranes in"/>
 <result pre="(6-HB), a common postfusion structure shared by all type I" exact="viral" post="glycoproteins, to bring viral and cellular membranes in close"/>
 <result pre="structure shared by all type I viral glycoproteins, to bring" exact="viral" post="and cellular membranes in close proximity. Additionally, the S2"/>
 <result pre="disordering properties residues 770â€&quot;788.25 Once in the host cell, the" exact="viral" post="particle uncoats and is ready for transcription and translation.26"/>
 <result pre="(NSPs), including RNA-dependent RNA polymerase (RdRp) and helicase, to catalyze" exact="viral" post="genome replication and protein synthesis.27 The remaining ORFs in"/>
 <result pre="that SARS-CoV-2 would behave similarly to SARS-CoV with regards to" exact="viral" post="entry and replication. Being the first step in the"/>
 <result pre="viral entry and replication. Being the first step in the" exact="infection" post="process, the entry of pathogenic viruses into susceptible cells"/>
 <result pre="As with other well-known viruses, such as HIV-1 and Ebola," exact="viral" post="entry of coronaviruses is a complex multiple-step process with"/>
 <result pre="encounter (in both the endosomal and nonendosomal pathway) in the" exact="viral" post="replication cycle and provides prophylactic intervention opportunities.34 SARS-CoV-2 spike"/>
 <result pre="analysis, and intervention at the RBD-ACE2 interface can potentially disrupt" exact="infection" post="efficiency. Recently the cryo-EM and crystal structures of SARS-CoV-2â€™s"/>
 <result pre="and loop 3â€&quot;4 (connecting Î²3 and Î²4) of ACE2 provide" exact="limited" post="contacts. At the N terminus of Î±1 (cluster 1),"/>
 <result pre="be considered carefully during the inhibitor design process. Figure 6" exact="Structural" post="alignment of the RBD-ACE2 interface from SARS-CoV-2 and SARS-CoV."/>
 <result pre="ref (30). Targeting the RBD Peptide Analogues, Monoclonal Antibodies, and" exact="Protein" post="Chimeras as RBD Inhibitors Both SARS-CoV and SARS-CoV-2 use"/>
 <result pre="As such, this critical interaction can be blocked to stop" exact="viral" post="entry.19 This strategy was first demonstrated by Hsiang et"/>
 <result pre="the SARS-CoV S protein-ACE2 interaction by small peptides. From a" exact="total" post="of 14 designed peptides, peptides SP-4, SP-8, and SP-10"/>
 <result pre="(IFA) studies with S-protein-pseudotyped retroviruses, revealed a novel mechanism of" exact="infection" post="inhibition of Vero E6 cells by SP-10.37 Structural investigation"/>
 <result pre="mechanism of infection inhibition of Vero E6 cells by SP-10.37" exact="Structural" post="investigation of the RBD-ACE2 complex by Michael et al."/>
 <result pre="crucial charged residues between positions 22 and 57 for SARS-CoV" exact="viral" post="entry. This structural information resulted in the design of"/>
 <result pre="applications for diagnosis, prophylaxis, and treatment of established and evolving" exact="viral" post="infections.39âˆ’41 Prabhakar et al. isolated specific antibodies from B"/>
 <result pre="40 mg/kg of mAb 201 or mAb 68 before SARS-CoV" exact="infection" post="showed complete protection from reinfection of lung tissues.43,44 Cross-reactivity"/>
 <result pre="of mAb 201 or mAb 68 before SARS-CoV infection showed" exact="complete" post="protection from reinfection of lung tissues.43,44 Cross-reactivity of mAbs"/>
 <result pre="received 200 Î¼g of m396 were nearly completely protected from" exact="infection" post="by Urbani and GD03 virus strains.46 M396 did compete"/>
 <result pre="noncompeting monoclonal antibodies that target MERS-CoV S protein and block" exact="viral" post="entry into host cells. Among them, two antibodies, REGN3051"/>
 <result pre="cross-neutralizing activity of SARS-CoV-S protein and SARS-CoV-2-S protein pseudotyped VSV" exact="infection" post="with IC50 values of 0.19 and 0.57 Î¼M, respectively.51"/>
 <result pre="ACE2 administrated with 0.3 mg of Ig1 ab1 prior intranasal" exact="infection" post="with SARS-CoV-2 did not show any detectable replication-competent virus,"/>
 <result pre="step in the HCoV-229E life cycle and may interact with" exact="viral" post="particles, thus inactivating their binding.58 Targeting the Cellular Receptor"/>
 <result pre="ACE2 Inhibitors Human angiotensin-converting enzyme (ACE) is a highly glycosylated" exact="type I" post="integral membrane protein and has been identified as a"/>
 <result pre="cell-specific expression also suggests a role in the regulation of" exact="cardiovascular" post="and renal function and fertility.60 ACE2 is a functional"/>
 <result pre="fertility.60 ACE2 is a functional receptor to the SARS-CoV during" exact="viral" post="entry, and recent research demonstrated that SARS-CoV-2 also utilizes"/>
 <result pre="urgent need to develop specific ACE2 inhibitors that would prevent" exact="infection" post="by both SARS-CoV and SARS-CoV-2. One of the first"/>
 <result pre="2) could target ACE2, and showed antiviral activity against SARS-CoV" exact="infection" post="in vitro, with an EC50 value of 41.6 Î¼M,"/>
 <result pre="field, combining the best attributes of antibodies and small molecules." exact="Linear" post="peptides are often highly flexible and unstructured in solution,"/>
 <result pre="thus is specific to ACE2. In addition, DX600 was chemically" exact="stable" post="and not hydrolyzable by ACE2.65 Although it is not"/>
 <result pre="not available to date.66 Chloroquine (4) currently has applications for" exact="malaria" post="and amoebiasis treatment. Interestingly, Nichol et al. showed that"/>
 <result pre="to date.66 Chloroquine (4) currently has applications for malaria and" exact="amoebiasis" post="treatment. Interestingly, Nichol et al. showed that chloroquine could"/>
 <result pre="Î¼M.67 Recently, Wang et al. found that 4 blocked SARS-CoV-2" exact="virus infection," post="with an IC50 value of 1.13 Î¼M and a"/>
 <result pre="ACE2, undergoes proteolytic shedding, releasing an enzymatically active ectodomain during" exact="viral" post="entry.75 Further research identified that a disintegrin and metalloproteinase"/>
 <result pre="its ACE2 receptor and thus interfered with the process of" exact="viral" post="entry.79 Despite the availability of many compounds with inhibitory"/>
 <result pre="roles, in addition to its lung injury protective role in" exact="acute" post="respiratory distress syndrome from a variety of causes, including"/>
 <result pre="in addition to its lung injury protective role in acute" exact="respiratory" post="distress syndrome from a variety of causes, including SARS-CoV"/>
 <result pre="to its lung injury protective role in acute respiratory distress" exact="syndrome" post="from a variety of causes, including SARS-CoV infection.80,81 As"/>
 <result pre="hold greater promise. Interference with Membrane Fusion of the Spike" exact="Protein" post="Membrane fusion is a crucial step in the MERS/SARS"/>
 <result pre="Protein Membrane fusion is a crucial step in the MERS/SARS" exact="infection" post="cycle in both described pathways (see section 1). Within"/>
 <result pre="described pathways (see section 1). Within the endosomal/clathrin-dependent route, internalized" exact="viral" post="particles need to fuse with the endosomal membrane to"/>
 <result pre="(HR) regions in the S2 domain are crucial for the" exact="viral" post="membrane fusion event.84,85 HR1 and HR2 can interact with"/>
 <result pre="interact with each other to form a 6-HB to bring" exact="viral" post="and cellular membranes close (for exact location, see Figure"/>
 <result pre="to region HR2 within the HR. HR2-8 displayed in an" exact="infection" post="inhibition assay with pseudotyped SARS-CoV S protein in Vero"/>
 <result pre="and Table 2).84 Moreover, HR2-8 demonstrated concentration-dependent inhibition of HCoV-NL63" exact="infection" post="with an IC50 value of 0.5 Î¼M and a"/>
 <result pre="spanning residues 1251â€&quot;1286 in HR2 domains, could effectively inhibit MERS-CoV" exact="infection" post="and S protein-mediated membrane fusion (Figure 7 and Table"/>
 <result pre="intranasal administration to Ad5/hDPP4 transgenic mice protected them from MERS-CoV" exact="infection" post="and reduced the lung viral titers by more than"/>
 <result pre="mice protected them from MERS-CoV infection and reduced the lung" exact="viral" post="titers by more than 1000-fold. Moreover, combination treatment with"/>
 <result pre="directly reacts with the HR1 region and can competitively inhibit" exact="viral" post="6-HB formation. The pseudovirus assay suggested that the antiviral"/>
 <result pre="the antiviral activity of EK1 against HCoV-OC43, HCoV-NL63, and HCoV-229E" exact="infection" post="with IC50 values of 1.81, 6.02, and 3.35 Î¼M,"/>
 <result pre="received 5 mg/kg of EK1 were nearly completely protected from" exact="infection" post="by HCoV-OC43 and 200 Î¼g of EK1 against MERS-CoV"/>
 <result pre="potent inhibitory activity inhibit SARS-CoV-2 S-mediated membrane fusion and pseudovirus" exact="infection" post="with IC50 values of 1.3 and 15.8 nM, The"/>
 <result pre="received 0.5 mg/kg of EK1C4 were nearly completely protected from" exact="infection" post="by HCoV-OC43. These data suggested that EK1C4 could be"/>
 <result pre="that EK1C4 could be used for inhibition and treatment of" exact="infection" post="by currently circulating SARS-CoV-2.92 MERS-5HB, a polypeptide derived from"/>
 <result pre="Î¼M. HR derived peptides is a highly promising strategy for" exact="viral" post="fusion inhibition. Successful HR peptides have been used in"/>
 <result pre="S protein HR1 and HR2 domains, could competitively inhibit the" exact="viral" post="autologous 6-HB formation and inhibit HCoV-229E S protein-mediated virus-cell"/>
 <result pre="Î¼M. In addition, 229E-HR2P potentially inhibited pseudotyped and live HCoV-229E" exact="infection" post="with IC50 values of 0.5 and 1.7 Î¼M, respectively.94"/>
 <result pre="5 Î¼g/mL. Cell fusion assays indicate that 5H10 can inhibit" exact="viral" post="fusion and entry rather than viral attachment to the"/>
 <result pre="that 5H10 can inhibit viral fusion and entry rather than" exact="viral" post="attachment to the surface of host cells or cleavage"/>
 <result pre="SKOT20 restrict conformational changes within the S2 domain, essential for" exact="viral" post="entry.98 Taken together, the here presented peptide and mAb"/>
 <result pre="can bind avidly to the SARS-CoV S2 protein and inhibit" exact="viral" post="entry of SARS-CoV into Vero E6 cells with IC50"/>
 <result pre="of 12 and 13 were 240.0 and 14.62, respectively. Further" exact="acute" post="toxicity suggested that the 50% lethal doses of 12"/>
 <result pre="Targeting S2 Domain and Proteolytic Processing ADS-J1 (15), a potential" exact="viral" post="entry inhibitor, was reported by Ngai et al. The"/>
 <result pre="Zhao et al. demonstrated that 15 could also inhibit MERS-CoV" exact="infection" post="in a pseudovirus-based inhibition assay, with an IC50 value"/>
 <result pre="Recently, Wang et al. identified that 16 efficiently inhibited SARS-CoV-2" exact="virus infection" post="in vitro with an IC50 value of 4.11 Î¼M,"/>
 <result pre="Wang et al. identified that 16 efficiently inhibited SARS-CoV-2 virus" exact="infection" post="in vitro with an IC50 value of 4.11 Î¼M,"/>
 <result pre="a clinical pilot trial conducted with 36 patients with SARS-CoV-2" exact="virus infection" post="received 400 mg 16 three times a day for"/>
 <result pre="clinical pilot trial conducted with 36 patients with SARS-CoV-2 virus" exact="infection" post="received 400 mg 16 three times a day for"/>
 <result pre="this trial, patients with 16 showed a tendency to decrease" exact="viral" post="load as determined by RT-PCR and reduced mortality (0%"/>
 <result pre="Inhibitors Antibiotics that Target the Cathepsin L Proteinase During clathrin-dependent" exact="viral" post="entry, the host cellular cathepsin L protease plays a"/>
 <result pre="host cellular cathepsin L protease plays a key role in" exact="infection" post="efficiency by activation of the S protein into a"/>
 <result pre="In light of its vital role in the SARS CoV" exact="infection" post="cycle, cathepsin L is a desirable target to interfere"/>
 <result pre="a glycopeptide antibiotic, with applications in the treatment of serious" exact="infections" post="caused by Gram-positive bacteria such as Streptococcus and Staphylococcus"/>
 <result pre="17 specifically inhibited cathepsin L-mediated substrate cleavage and blocked SARS-CoV" exact="viral" post="entry, with an IC50 value of 2.5 nM and"/>
 <result pre="CID 23631927 (19), were reported by Diamond et al. as" exact="viral" post="entry inhibitors of the SARS-CoV. In a cathepsin L"/>
 <result pre="value of 273 nM) showed some inhibition activity for Ebola" exact="virus infection" post="(EC50 value of 193 nM) of human embryonic kidney"/>
 <result pre="of 273 nM) showed some inhibition activity for Ebola virus" exact="infection" post="(EC50 value of 193 nM) of human embryonic kidney"/>
 <result pre="to the cathepsin L proteinase and interference SARS-S protein during" exact="viral" post="entry, with an IC50 value of 5.33 Î¼M. In"/>
 <result pre="SARS-CoV virus entry into host cells by cleavage of the" exact="viral" post="S protein.19 This cleavage exposes fusion-competent motifs known as"/>
 <result pre="commercially available serine protease inhibitor that can efficiently prevent SARS-CoV" exact="infections" post="at 10 Î¼M by inhibiting TMPRSS2 activity. However, even"/>
 <result pre="at high concentrations (100 Î¼M) of 22, the inhibition of" exact="viral" post="entry via SARS S protein-mediated cell fusion never exceeded"/>
 <result pre="suggested that simultaneous treatment with EST and 22 remarkably blocked" exact="infection" post="(&amp;gt;95%).116 Similarly, PÃ¶hlmann et al. reported that 22 could"/>
 <result pre="Similarly, PÃ¶hlmann et al. reported that 22 could prevent the" exact="viral" post="entry of SARS-CoV-2. Importantly, full inhibition efficiency was attained"/>
 <result pre="of the Furin Cleavage Site in the Coronavirus Spike Proteins" exact="Elevated" post="levels of furin expression were able to facilitate MERS-CoV"/>
 <result pre="furin expression were able to facilitate MERS-CoV pseudovirion infection, and" exact="viral" post="entry could be reduced by furin siRNA silencing.20Decanoyl-RVKR-chloromethylketone (23,"/>
 <result pre="shown to block MERS-CoV S protein-mediated entry as well as" exact="virus infection," post="with an IC50 value of 75 Î¼M in HEK-293T"/>
 <result pre="furin inhibitors could play a significant role in blocking the" exact="viral" post="entry process.117,118 Host Factor Inhibitors SARS-CoV-2 cell entry also"/>
 <result pre="of schizophrenia. It has also been reported to inhibit the" exact="infection" post="of hepatic C virus (HCV),120 mouse hepatitis virus (MHV-2),27"/>
 <result pre="to inhibit the infection of hepatic C virus (HCV),120 mouse" exact="hepatitis" post="virus (MHV-2),27 and alphavirus.121 Recently, Liu et al. demonstrated"/>
 <result pre="identifies best-in-class drugs.127âˆ’129 Although the phenotypic screening approach often is" exact="limited" post="in terms of capacity compared to in silico target-based"/>
 <result pre="51 compounds inhibited virus entry, while 19 others interfered with" exact="viral" post="replication.133 Natural products should, however, be considered with caution"/>
 <result pre="as a global pandemic by the WHO. The number of" exact="infections" post="continues to rise, and numerous research groups around the"/>
 <result pre="COVID-19 treatments. Still, there are no effective treatments to date." exact="Viral" post="entry is the first step in the viral life"/>
 <result pre="to date. Viral entry is the first step in the" exact="viral" post="life cycle and represents an attractive intervention point by"/>
 <result pre="virusâ€&quot;cell membrane fusion event. SARS-CoV-2 and other coronaviruses have similar" exact="infection" post="mechanisms. This is especially true for SARS-CoV and CoV-NL63,"/>
 <result pre="CoV-NL63, which share the same human ACE2 receptor crucial for" exact="viral" post="entry. Therefore, already developed inhibitors against known hCoVs could"/>
 <result pre="anticoronavirus activity. Although many inhibitors demonstrated efficacy in inhibiting coronavirus" exact="virus infection," post="no specific prophylactic or postexposure therapy is currently available"/>
 <result pre="safety data in hand. The most effective measure to prevent" exact="viral" post="diseases is vaccination. Coronavirus vaccine development mainly focused on"/>
 <result pre="in the context of previous epidemics, no vaccine for SARS-CoV-2" exact="infections" post="is yet available. Since the recent SARS-CoV-2 outbreak, research"/>
 <result pre="targeting SARS-CoV-2, and vaccine research routes include nucleic acid vaccines," exact="viral" post="vector vaccines, inactivated vaccines, and recombinant protein vaccines. Typical"/>
 <result pre="option for COVID-19 treatment. Passive immunization was well established for" exact="viral infection" post="prophylaxis.138 By meta-analysis of studies about the 1918 influenza,"/>
 <result pre="for COVID-19 treatment. Passive immunization was well established for viral" exact="infection" post="prophylaxis.138 By meta-analysis of studies about the 1918 influenza,"/>
 <result pre="of convalescent blood products decreased the risk ratio caused by" exact="pneumonia" post="from 37% to 16%.139 Nevertheless, the appropriate titer of"/>
 <result pre="out with MERS-CoV suggested that sera from patients recovering from" exact="infections" post="did not contain sufficient antibody titers for therapeutic use.140"/>
 <result pre="group of Dr. Simon Cocklin and is currently working in" exact="infectious" post="disease-related (HIV-1, Ebola virus, SARS-CoV-2) computationally aided drug design"/>
 <result pre="molecules that interact with specific enzymes and receptors in the" exact="viral" post="life cycle. Other ongoing programs include studies of the"/>
 <result pre="and structureâ€&quot;activity relationships of some natural products used to treat" exact="cardiovascular" post="diseases, and drug delivery research using PEGylated small-molecular agents."/>
 <result pre="A disintegrin and metalloproteinase bnAbs broadly neutralizing antibodies COVID-19 coronavirus" exact="disease" post="2019 CPE cytopathic effect ELISA enzyme-linked immunosorbent assay FP"/>
 <result pre="feline coronavirus HR heptad repeat HA hemagglutinin HIV human immune" exact="deficiency" post="virus HCoV human coronaviruse HTS high-throughput screen HCV hepatic"/>
 <result pre="virus IFA immunofluorescence assay KM immunized Kunming MERS-CoV Middle East" exact="respiratory" post="syndrome coronavirus MHV mouse hepatitis coronavirus NTD N-terminal domain"/>
 <result pre="IFA immunofluorescence assay KM immunized Kunming MERS-CoV Middle East respiratory" exact="syndrome" post="coronavirus MHV mouse hepatitis coronavirus NTD N-terminal domain PD"/>
 <result pre="immunized Kunming MERS-CoV Middle East respiratory syndrome coronavirus MHV mouse" exact="hepatitis" post="coronavirus NTD N-terminal domain PD proteolytic domain PBPK physiologically"/>
 <result pre="domain RdRp RNA-dependent RNA polymerase RAS renin-angiotensin system SARS-CoV severe" exact="acute" post="respiratory syndrome coronavirus SPR surface plasmon resonance SFKs Src-family"/>
 <result pre="RdRp RNA-dependent RNA polymerase RAS renin-angiotensin system SARS-CoV severe acute" exact="respiratory" post="syndrome coronavirus SPR surface plasmon resonance SFKs Src-family of"/>
 <result pre="RNA-dependent RNA polymerase RAS renin-angiotensin system SARS-CoV severe acute respiratory" exact="syndrome" post="coronavirus SPR surface plasmon resonance SFKs Src-family of tyrosine"/>
 <result pre="10.1016/j.drudis.2020.01.015.32006468 WeissS. R.; Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe" exact="acute" post="respiratory syndrome coronavirus. Microbiol. Mol. Biol. Rev.2005, 69, 635â€&quot;664."/>
 <result pre="WeissS. R.; Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe acute" exact="respiratory" post="syndrome coronavirus. Microbiol. Mol. Biol. Rev.2005, 69, 635â€&quot;664. 10.1128/MMBR.69.4.635-664.2005.16339739"/>
 <result pre="R.; Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe acute respiratory" exact="syndrome" post="coronavirus. Microbiol. Mol. Biol. Rev.2005, 69, 635â€&quot;664. 10.1128/MMBR.69.4.635-664.2005.16339739 TongT."/>
 <result pre="10.1128/MMBR.69.4.635-664.2005.16339739 TongT. R.Therapies for coronaviruses. Part I of II --" exact="viral" post="entry inhibitors. Expert Opin. Ther. Pat.2009, 19, 357â€&quot;367. 10.1517/13543770802609384.19449500"/>
 <result pre="F.; OlingerG. G.; HensleyL. E.; FriemanM. B.; JahrlingP. B.Middle east" exact="respiratory" post="syndrome and severe acute respiratory syndrome: current therapeutic options"/>
 <result pre="OlingerG. G.; HensleyL. E.; FriemanM. B.; JahrlingP. B.Middle east respiratory" exact="syndrome" post="and severe acute respiratory syndrome: current therapeutic options and"/>
 <result pre="E.; FriemanM. B.; JahrlingP. B.Middle east respiratory syndrome and severe" exact="acute" post="respiratory syndrome: current therapeutic options and potential targets for"/>
 <result pre="FriemanM. B.; JahrlingP. B.Middle east respiratory syndrome and severe acute" exact="respiratory" post="syndrome: current therapeutic options and potential targets for novel"/>
 <result pre="C.; LowD. E.; PetricM.; RoperR. L.; TalbotP. J.; TamT.; BabiukL.Severe" exact="acute" post="respiratory syndrome (SARS): a year in review. Annu. Rev."/>
 <result pre="LowD. E.; PetricM.; RoperR. L.; TalbotP. J.; TamT.; BabiukL.Severe acute" exact="respiratory" post="syndrome (SARS): a year in review. Annu. Rev. Med.2005,"/>
 <result pre="E.; PetricM.; RoperR. L.; TalbotP. J.; TamT.; BabiukL.Severe acute respiratory" exact="syndrome" post="(SARS): a year in review. Annu. Rev. Med.2005, 56,"/>
 <result pre="in review. Annu. Rev. Med.2005, 56, 357â€&quot;381. 10.1146/annurev.med.56.091103.134135.15660517 Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV); World Health Organization, 2020; https://www.who.int/emergencies/mers-cov/en/ (accessed"/>
 <result pre="review. Annu. Rev. Med.2005, 56, 357â€&quot;381. 10.1146/annurev.med.56.091103.134135.15660517 Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV); World Health Organization, 2020; https://www.who.int/emergencies/mers-cov/en/ (accessed 2020-05-29)."/>
 <result pre="targeting the spike protein of SARS-CoV-2. Peptides2020, 130, 17032810.1016/j.peptides.2020.170328.32380200 Coronavirus" exact="Disease" post="(COVID-2019) Situation Reports; World Health Organization, 2020; https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed"/>
 <result pre="Situation Reports; World Health Organization, 2020; https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed 2020-05-29). Coronavirus" exact="Disease" post="2019 (COVID-19); Centers for Disease Control and Prevention, 2020;"/>
 <result pre="2020; https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed 2020-05-29). Coronavirus Disease 2019 (COVID-19); Centers for" exact="Disease" post="Control and Prevention, 2020; https://www.cdc.gov/coronavirus/2019-ncov/locations-confirmed-cases.html#map (accessed 2020-05-27 2020). ZhouP.;"/>
 <result pre="L.; YanB.; ZhanF. X.; WangY. Y.; XiaoG. F.; ShiZ. L.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="TanakaN.; TanakaY.; InoueS.; MoritaK.; ZhuangM.; HattoriT.; SugamuraK.Clathrin-dependent entry of severe" exact="acute" post="respiratory syndrome coronavirus into target cells expressing ACE2 with"/>
 <result pre="TanakaY.; InoueS.; MoritaK.; ZhuangM.; HattoriT.; SugamuraK.Clathrin-dependent entry of severe acute" exact="respiratory" post="syndrome coronavirus into target cells expressing ACE2 with the"/>
 <result pre="InoueS.; MoritaK.; ZhuangM.; HattoriT.; SugamuraK.Clathrin-dependent entry of severe acute respiratory" exact="syndrome" post="coronavirus into target cells expressing ACE2 with the cytoplasmic"/>
 <result pre="L.; Dâ€™SouzaR. S.; CasanovaJ. E.; WhiteJ. M.Ebola virus and severe" exact="acute" post="respiratory syndrome coronavirus display late cell entry kinetics: evidence"/>
 <result pre="Dâ€™SouzaR. S.; CasanovaJ. E.; WhiteJ. M.Ebola virus and severe acute" exact="respiratory" post="syndrome coronavirus display late cell entry kinetics: evidence that"/>
 <result pre="S.; CasanovaJ. E.; WhiteJ. M.Ebola virus and severe acute respiratory" exact="syndrome" post="coronavirus display late cell entry kinetics: evidence that transport"/>
 <result pre="CD147-spike protein. BioRxiv. 2020, 988345, 10.1101/2020.03.14.988345. ShiratoK.; KawaseM.; MatsuyamaS.Middle East" exact="respiratory" post="syndrome coronavirus infection mediated by the transmembrane serine protease"/>
 <result pre="protein. BioRxiv. 2020, 988345, 10.1101/2020.03.14.988345. ShiratoK.; KawaseM.; MatsuyamaS.Middle East respiratory" exact="syndrome" post="coronavirus infection mediated by the transmembrane serine protease TMPRSS2."/>
 <result pre="2020, 988345, 10.1101/2020.03.14.988345. ShiratoK.; KawaseM.; MatsuyamaS.Middle East respiratory syndrome coronavirus" exact="infection" post="mediated by the transmembrane serine protease TMPRSS2. J. Virol.2013,"/>
 <result pre="10.1016/j.cell.2020.02.052.32142651 MilletJ. K.; WhittakerG. R.Host cell entry of Middle East" exact="respiratory" post="syndrome coronavirus after two-step, furin-mediated activation of the spike"/>
 <result pre="MilletJ. K.; WhittakerG. R.Host cell entry of Middle East respiratory" exact="syndrome" post="coronavirus after two-step, furin-mediated activation of the spike protein."/>
 <result pre="a determinant of influenza pathogenicity and the origin of the" exact="labile" post="conformation. Cell1998, 95, 409â€&quot;417. 10.1016/S0092-8674(00)81771-7.9814710 MaduI. G.; RothS. L.;"/>
 <result pre="WhittakerG. R.Characterization of a highly conserved domain within the severe" exact="acute" post="respiratory syndrome coronavirus spike protein S2 domain with characteristics"/>
 <result pre="R.Characterization of a highly conserved domain within the severe acute" exact="respiratory" post="syndrome coronavirus spike protein S2 domain with characteristics of"/>
 <result pre="of a highly conserved domain within the severe acute respiratory" exact="syndrome" post="coronavirus spike protein S2 domain with characteristics of a"/>
 <result pre="syndrome coronavirus spike protein S2 domain with characteristics of a" exact="viral" post="fusion peptide. J. Virol.2009, 83, 7411â€&quot;7421. 10.1128/JVI.00079-09.19439480 PetitC. M.;"/>
 <result pre="and characterization of the putative fusion peptide of the severe" exact="acute" post="respiratory syndrome-associated coronavirus spike protein. J. Virol.2005, 79, 7195â€&quot;7206."/>
 <result pre="characterization of the putative fusion peptide of the severe acute" exact="respiratory" post="syndrome-associated coronavirus spike protein. J. Virol.2005, 79, 7195â€&quot;7206. 10.1128/JVI.79.11.7195-7206.2005.15890958"/>
 <result pre="systematic review. Indian J. Pharmacol.2020, 52, 56â€&quot;65. 10.4103/ijp.IJP_115_20.32201449 PuY.; ZhangX.Mouse" exact="hepatitis" post="virus type 2 enters cells through a clathrin-mediated endocytic"/>
 <result pre="Indian J. Pharmacol.2020, 52, 56â€&quot;65. 10.4103/ijp.IJP_115_20.32201449 PuY.; ZhangX.Mouse hepatitis virus" exact="type 2" post="enters cells through a clathrin-mediated endocytic pathway independent of"/>
 <result pre="for controlling emerging coronaviruses. Nat. Rev. Microbiol.2013, 11, 836â€&quot;848. 10.1038/nrmicro3143.24217413" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 Isolate Wuhan-Hu-1, Complete Genome;"/>
 <result pre="controlling emerging coronaviruses. Nat. Rev. Microbiol.2013, 11, 836â€&quot;848. 10.1038/nrmicro3143.24217413 Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 Isolate Wuhan-Hu-1, Complete Genome; National"/>
 <result pre="emerging coronaviruses. Nat. Rev. Microbiol.2013, 11, 836â€&quot;848. 10.1038/nrmicro3143.24217413 Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 Isolate Wuhan-Hu-1, Complete Genome; National Center"/>
 <result pre="coronaviruses. Nat. Rev. Microbiol.2013, 11, 836â€&quot;848. 10.1038/nrmicro3143.24217413 Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 Isolate Wuhan-Hu-1, Complete Genome; National Center for"/>
 <result pre="836â€&quot;848. 10.1038/nrmicro3143.24217413 Severe Acute Respiratory Syndrome Coronavirus 2 Isolate Wuhan-Hu-1," exact="Complete" post="Genome; National Center for Biotechnology Information, 2020; https://go.usa.gov/xwGE3 (accessed"/>
 <result pre="XuL.; HolmesE. C.; ZhangY. Z.A new coronavirus associated with human" exact="respiratory" post="disease in China. Nature2020, 579, 265â€&quot;269. 10.1038/s41586-020-2008-3.32015508 YanR.; ZhangY.;"/>
 <result pre="HolmesE. C.; ZhangY. Z.A new coronavirus associated with human respiratory" exact="disease" post="in China. Nature2020, 579, 265â€&quot;269. 10.1038/s41586-020-2008-3.32015508 YanR.; ZhangY.; LiY.;"/>
 <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoV. ChemBioChem2020, 21, 730â€&quot;738. 10.1002/cbic.202000047.32022370"/>
 <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoV. ChemBioChem2020, 21, 730â€&quot;738. 10.1002/cbic.202000047.32022370 GuJ.;"/>
 <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoV. ChemBioChem2020, 21, 730â€&quot;738. 10.1002/cbic.202000047.32022370 GuJ.; KortewegC.Pathology"/>
 <result pre="ChemBioChem2020, 21, 730â€&quot;738. 10.1002/cbic.202000047.32022370 GuJ.; KortewegC.Pathology and pathogenesis of severe" exact="acute" post="respiratory syndrome. Am. J. Pathol.2007, 170, 1136â€&quot;1147. 10.2353/ajpath.2007.061088.17392154 OrtegaJ."/>
 <result pre="21, 730â€&quot;738. 10.1002/cbic.202000047.32022370 GuJ.; KortewegC.Pathology and pathogenesis of severe acute" exact="respiratory" post="syndrome. Am. J. Pathol.2007, 170, 1136â€&quot;1147. 10.2353/ajpath.2007.061088.17392154 OrtegaJ. T.;"/>
 <result pre="MarinelloP.; RochaS. P.D.; Faccin-GalhardiL. C.Antibody therapy for the control of" exact="viral" post="diseases: an update. Curr. Pharm. Biotechnol.2019, 20, 1108â€&quot;1121. 10.2174/1389201020666190809112704.31400263"/>
 <result pre="1108â€&quot;1121. 10.2174/1389201020666190809112704.31400263 MeulenJ. t.Monoclonal antibodies for prophylaxis and therapy of" exact="infectious diseases." post="Expert Opin. Emerging Drugs2007, 12, 525â€&quot;540. 10.1517/14728214.12.4.525. XiaoX.; DimitrovD."/>
 <result pre="CoughlinM. M.; BabcookJ.; PrabhakarB. S.Human monoclonal antibodies to SARS-coronavirus inhibit" exact="infection" post="by different mechanisms. Virology2009, 394, 39â€&quot;46. 10.1016/j.virol.2009.07.028.19748648 GreenoughT. C.;"/>
 <result pre="LuzuriagaK.; SullivanJ. L.; AmbrosinoD. M.Development and characterization of a severe" exact="acute" post="respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective"/>
 <result pre="SullivanJ. L.; AmbrosinoD. M.Development and characterization of a severe acute" exact="respiratory" post="syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis"/>
 <result pre="GanJ.; FengY.; ZhuZ.; ChoudhryV.; XiaoX.; JiX.; DimitrovD. S.Structure of severe" exact="acute" post="respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody."/>
 <result pre="FengY.; ZhuZ.; ChoudhryV.; XiaoX.; JiX.; DimitrovD. S.Structure of severe acute" exact="respiratory" post="syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J."/>
 <result pre="ZhuZ.; ChoudhryV.; XiaoX.; JiX.; DimitrovD. S.Structure of severe acute respiratory" exact="syndrome" post="coronavirus receptor-binding domain complexed with neutralizing antibody. J. Biol."/>
 <result pre="SeversonW.; JonssonC.; SinghK.; WeissS. R.; SarafianosS. G.Novel inhibitors of severe" exact="acute" post="respiratory syndrome coronavirus entry that act by three distinct"/>
 <result pre="JonssonC.; SinghK.; WeissS. R.; SarafianosS. G.Novel inhibitors of severe acute" exact="respiratory" post="syndrome coronavirus entry that act by three distinct mechanisms."/>
 <result pre="SinghK.; WeissS. R.; SarafianosS. G.Novel inhibitors of severe acute respiratory" exact="syndrome" post="coronavirus entry that act by three distinct mechanisms. J."/>
 <result pre="R.; MuthD.; KintJ.; ForlenzaM.; MÃ¼llerM. A.; DrostenC.; ThielV.; TrybalaE.Targeting membrane-bound" exact="viral" post="RNA synthesis reveals potent inhibition of diverse coronaviruses including"/>
 <result pre="reveals potent inhibition of diverse coronaviruses including the Middle East" exact="respiratory" post="syndrome virus. PLoS Pathog.2014, 10, e100416610.1371/journal.ppat.1004166.24874215 TurnerA. J.Angiotensin-converting enzyme"/>
 <result pre="potent inhibition of diverse coronaviruses including the Middle East respiratory" exact="syndrome" post="virus. PLoS Pathog.2014, 10, e100416610.1371/journal.ppat.1004166.24874215 TurnerA. J.Angiotensin-converting enzyme 2:"/>
 <result pre="identification of linear B-cell epitopes and entry-blocking peptide of severe" exact="acute" post="respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library."/>
 <result pre="of linear B-cell epitopes and entry-blocking peptide of severe acute" exact="respiratory" post="syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. J."/>
 <result pre="linear B-cell epitopes and entry-blocking peptide of severe acute respiratory" exact="syndrome" post="(SARS)-associated coronavirus using synthetic overlapping peptide library. J. Comb."/>
 <result pre="the receptor-binding domain of SARS corona virus spike protein blocks" exact="viral" post="entry into host cells via the human receptor ACE2."/>
 <result pre="G.; NicholS. T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol. J.2005, 2, 6910.1186/1743-422X-2-69.16115318 WangM.; CaoR.; ZhangL.;"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studies. BioSci. Trends2020, 14, 72â€&quot;73. 10.5582/bst.2020.01047.32074550 RainsfordK."/>
 <result pre="and pharmacological properties of hydroxychloroquine and chloroquine in treatment of" exact="systemic" post="lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology2015, 23,"/>
 <result pre="pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic" exact="lupus erythematosus," post="rheumatoid arthritis and related diseases. Inflammopharmacology2015, 23, 231â€&quot;269. 10.1007/s10787-015-0239-y.26246395"/>
 <result pre="of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus," exact="rheumatoid arthritis" post="and related diseases. Inflammopharmacology2015, 23, 231â€&quot;269. 10.1007/s10787-015-0239-y.26246395 YaoX.; YeF.;"/>
 <result pre="hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid" exact="arthritis" post="and related diseases. Inflammopharmacology2015, 23, 231â€&quot;269. 10.1007/s10787-015-0239-y.26246395 YaoX.; YeF.;"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis.2020, ciaa23710.1093/cid/ciaa237.32150618"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis.2020, ciaa23710.1093/cid/ciaa237.32150618 ChenC.;"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis.2020, ciaa23710.1093/cid/ciaa237.32150618 ChenC.; WangF.;"/>
 <result pre="44, 173â€&quot;175. 10.1080/15563650500514558. StasP.; FaesD.; NoyensP.Conduction disorder and qt prolongation" exact="secondary" post="to long-term treatment with chloroquine. Int. J. Cardiol.2008, 127,"/>
 <result pre="factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute" exact="respiratory" post="syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem.2005,"/>
 <result pre="SlutskyA. S.; JiangC.; PenningerJ. M.Angiotensin-converting enzyme 2 protects from severe" exact="acute" post="lung failure. Nature2005, 436, 112â€&quot;116. 10.1038/nature03712.16001071 ImaiY.; KubaK.; PenningerJ."/>
 <result pre="M.The discovery of angiotensin-converting enzyme 2 and its role in" exact="acute" post="lung injury in mice. Exp. Physiol.2008, 93, 543â€&quot;548. 10.1113/expphysiol.2007.040048.18448662"/>
 <result pre="ReevesJ. D.; DiamondS. L.; BatesP.Inhibitors of cathepsin L prevent severe" exact="acute" post="respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. U."/>
 <result pre="D.; DiamondS. L.; BatesP.Inhibitors of cathepsin L prevent severe acute" exact="respiratory" post="syndrome coronavirus entry. Proc. Natl. Acad. Sci. U. S."/>
 <result pre="DiamondS. L.; BatesP.Inhibitors of cathepsin L prevent severe acute respiratory" exact="syndrome" post="coronavirus entry. Proc. Natl. Acad. Sci. U. S. A.2005,"/>
 <result pre="R.; de GrootR.; OsterhausA. D. M. E.; RottierP. J. M.Severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein"/>
 <result pre="de GrootR.; OsterhausA. D. M. E.; RottierP. J. M.Severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad"/>
 <result pre="GrootR.; OsterhausA. D. M. E.; RottierP. J. M.Severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived"/>
 <result pre="M. E.; RottierP. J. M.Severe acute respiratory syndrome coronavirus (SARS-CoV)" exact="infection" post="inhibition using spike protein heptad repeat-derived peptides. Proc. Natl."/>
 <result pre="F.; DijkmanR.; RottierP.; van der HoekL.Inhibition of human coronavirus NL63" exact="infection" post="at early stages of the replication cycle. Antimicrob. Agents"/>
 <result pre="B.; WayeM. M.; NgaiS. M.Fusion core structure of the severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV"/>
 <result pre="WayeM. M.; NgaiS. M.Fusion core structure of the severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry"/>
 <result pre="M.; NgaiS. M.Fusion core structure of the severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors."/>
 <result pre="MaC.; YeS.; YuenK. Y.; ZhangR.; JiangS.Structure-based discovery of Middle East" exact="respiratory" post="syndrome coronavirus fusion inhibitor. Nat. Commun.2014, 5, 306710.1038/ncomms4067.24473083 ChannappanavarR.;"/>
 <result pre="YeS.; YuenK. Y.; ZhangR.; JiangS.Structure-based discovery of Middle East respiratory" exact="syndrome" post="coronavirus fusion inhibitor. Nat. Commun.2014, 5, 306710.1038/ncomms4067.24473083 ChannappanavarR.; LuL.;"/>
 <result pre="PerlmanS.; JiangS.Protective effect of intranasal regimens containing peptidic middle east" exact="respiratory" post="syndrome coronavirus fusion inhibitor against mers-cov infection. J. Infect."/>
 <result pre="JiangS.Protective effect of intranasal regimens containing peptidic middle east respiratory" exact="syndrome" post="coronavirus fusion inhibitor against mers-cov infection. J. Infect. Dis.2015,"/>
 <result pre="QinC.; SunF.; ShiZ. L.; ZhuY.; JiangS. B.; LuL.Inhibition of SARS-CoV-2" exact="infection" post="(previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor"/>
 <result pre="ShiJ.; ZhangZ.; GongR.Identification of a novel inhibitor against Middle East" exact="respiratory" post="syndrome coronavirus. Viruses2017, 9, 25510.3390/v9090255. XiaS.; XuW.; WangQ.; WangC.;"/>
 <result pre="ZhangZ.; GongR.Identification of a novel inhibitor against Middle East respiratory" exact="syndrome" post="coronavirus. Viruses2017, 9, 25510.3390/v9090255. XiaS.; XuW.; WangQ.; WangC.; HuaC.;"/>
 <result pre="human monoclonal antibody directed to proteolytic cleavage site in severe" exact="acute" post="respiratory syndrome (SARS) coronavirus S protein neutralizes the virus"/>
 <result pre="monoclonal antibody directed to proteolytic cleavage site in severe acute" exact="respiratory" post="syndrome (SARS) coronavirus S protein neutralizes the virus in"/>
 <result pre="antibody directed to proteolytic cleavage site in severe acute respiratory" exact="syndrome" post="(SARS) coronavirus S protein neutralizes the virus in a"/>
 <result pre="LiuY.; DingM.; DengH.; XuX.Small molecules blocking the entry of severe" exact="acute" post="respiratory syndrome coronavirus into host cells. J. Virol.2004, 78,"/>
 <result pre="DingM.; DengH.; XuX.Small molecules blocking the entry of severe acute" exact="respiratory" post="syndrome coronavirus into host cells. J. Virol.2004, 78, 11334â€&quot;11339."/>
 <result pre="DengH.; XuX.Small molecules blocking the entry of severe acute respiratory" exact="syndrome" post="coronavirus into host cells. J. Virol.2004, 78, 11334â€&quot;11339. 10.1128/JVI.78.20.11334-11339.2004.15452254"/>
 <result pre="pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for" exact="viral" post="entry inhibitors against the novel human coronavirus MERS-CoV. Virol."/>
 <result pre="YangB.; LiQ.; WenL.; ZhangR.Clinical features of 69 cases with coronavirus" exact="disease" post="2019 in Wuhan, China. Clin. Infect. Dis.2020, ciaa27210.1093/cid/ciaa272.32176772 BoschB."/>
 <result pre="BoschB. J.; BartelinkW.; RottierP. J.Cathepsin L functionally cleaves the severe" exact="acute" post="respiratory syndrome coronavirus class I fusion protein upstream of"/>
 <result pre="J.; BartelinkW.; RottierP. J.Cathepsin L functionally cleaves the severe acute" exact="respiratory" post="syndrome coronavirus class I fusion protein upstream of rather"/>
 <result pre="BartelinkW.; RottierP. J.Cathepsin L functionally cleaves the severe acute respiratory" exact="syndrome" post="coronavirus class I fusion protein upstream of rather than"/>
 <result pre="KainsJ. P.; Serruys-SchoutensE.Clinical evaluation of teicoplanin for therapy of severe" exact="infections" post="caused by gram-positive bacteria. Antimicrob. Agents Chemother.1986, 29, 52â€&quot;57."/>
 <result pre="endosome/lysosome and block the entry of Ebola virus, Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus"/>
 <result pre="and block the entry of Ebola virus, Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)."/>
 <result pre="Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV). J. Biol. Chem.2016, 291, 9218â€&quot;9232."/>
 <result pre="virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV). J. Biol. Chem.2016, 291, 9218â€&quot;9232. 10.1074/jbc.M116.716100.26953343"/>
 <result pre="Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV). J. Biol. Chem.2016, 291, 9218â€&quot;9232. 10.1074/jbc.M116.716100.26953343 ZhangJ."/>
 <result pre="L.A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe" exact="acute" post="respiratory syndrome and ebola pseudotype virus infection into human"/>
 <result pre="small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute" exact="respiratory" post="syndrome and ebola pseudotype virus infection into human embryonic"/>
 <result pre="oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory" exact="syndrome" post="and ebola pseudotype virus infection into human embryonic kidney"/>
 <result pre="cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype" exact="virus infection" post="into human embryonic kidney 293T cells. Mol. Pharmacol.2010, 78,"/>
 <result pre="L blocks severe acute respiratory syndrome and ebola pseudotype virus" exact="infection" post="into human embryonic kidney 293T cells. Mol. Pharmacol.2010, 78,"/>
 <result pre="ShiratoK.; van der HoekL.; TaguchiF.; MatsuyamaS.Simultaneous treatment of human bronchial" exact="epithelial" post="cells with serine and cysteine protease inhibitors prevents severe"/>
 <result pre="epithelial cells with serine and cysteine protease inhibitors prevents severe" exact="acute" post="respiratory syndrome coronavirus entry. J. Virol.2012, 86, 6537â€&quot;6545. 10.1128/JVI.00094-12.22496216"/>
 <result pre="cells with serine and cysteine protease inhibitors prevents severe acute" exact="respiratory" post="syndrome coronavirus entry. J. Virol.2012, 86, 6537â€&quot;6545. 10.1128/JVI.00094-12.22496216 BestleD.;"/>
 <result pre="with serine and cysteine protease inhibitors prevents severe acute respiratory" exact="syndrome" post="coronavirus entry. J. Virol.2012, 86, 6537â€&quot;6545. 10.1128/JVI.00094-12.22496216 BestleD.; HeindlM."/>
 <result pre="for proteolytic activation and spread of SARS-CoV-2 in human airway" exact="epithelial" post="cells and provide promising drug targets. BioRxiv2020, 042085 DOI:"/>
 <result pre="site in the spike protein of SARS-CoV-2 is essential for" exact="infection" post="of human lung cells. Mol. Cell2020, 78, 779â€&quot;784. 10.1016/j.molcel.2020.04.022.32362314"/>
 <result pre="AbrahamP.; GangakhedkarR. R.; BhargavaB.Perspectives for repurposing drugs for the coronavirus" exact="disease" post="2019. Indian J. Med. Res.2020, 151, 160â€&quot;171. 10.4103/ijmr.IJMR_585_20.32317408 BlanchardE.;"/>
 <result pre="AholaT.; TammelaP.Inhibitors of alphavirus entry and replication identified with a" exact="stable" post="chikungunya replicon cell line and virus-based assays. PLoS One2011,"/>
 <result pre="TammelaP.Inhibitors of alphavirus entry and replication identified with a stable" exact="chikungunya" post="replicon cell line and virus-based assays. PLoS One2011, 6,"/>
 <result pre="LiuQ.; XiaS.; SunZ.; WangQ.; DuL.; LuL.; JiangS.Testing of Middle East" exact="respiratory" post="syndrome coronavirus replication inhibitors for the ability to block"/>
 <result pre="XiaS.; SunZ.; WangQ.; DuL.; LuL.; JiangS.Testing of Middle East respiratory" exact="syndrome" post="coronavirus replication inhibitors for the ability to block viral"/>
 <result pre="respiratory syndrome coronavirus replication inhibitors for the ability to block" exact="viral" post="entry. Antimicrob. Agents Chemother.2015, 59, 742â€&quot;744. 10.1128/AAC.03977-14.25331705 SiskJ. M.;"/>
 <result pre="M.; FriemanM. B.Abelson kinase inhibitors are potent inhibitors of severe" exact="acute" post="respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus"/>
 <result pre="FriemanM. B.Abelson kinase inhibitors are potent inhibitors of severe acute" exact="respiratory" post="syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion."/>
 <result pre="B.Abelson kinase inhibitors are potent inhibitors of severe acute respiratory" exact="syndrome" post="coronavirus and Middle East respiratory syndrome coronavirus fusion. J."/>
 <result pre="inhibitors of severe acute respiratory syndrome coronavirus and Middle East" exact="respiratory" post="syndrome coronavirus fusion. J. Virol.2016, 90, 8924â€&quot;8933. 10.1128/JVI.01429-16.27466418 DyallJ.;"/>
 <result pre="of severe acute respiratory syndrome coronavirus and Middle East respiratory" exact="syndrome" post="coronavirus fusion. J. Virol.2016, 90, 8924â€&quot;8933. 10.1128/JVI.01429-16.27466418 DyallJ.; ColemanC."/>
 <result pre="B.Repurposing of clinically developed drugs for treatment of middle east" exact="respiratory" post="syndrome coronavirus infection. Antimicrob. Agents Chemother.2014, 58, 4885â€&quot;4893. 10.1128/AAC.03036-14.24841273"/>
 <result pre="of clinically developed drugs for treatment of middle east respiratory" exact="syndrome" post="coronavirus infection. Antimicrob. Agents Chemother.2014, 58, 4885â€&quot;4893. 10.1128/AAC.03036-14.24841273 ShinJ."/>
 <result pre="S.; JungE.; KimM.; BaricR. S.; GoY. Y.Saracatinib inhibits middle east" exact="respiratory" post="syndrome-coronavirus replication in vitro. Viruses2018, 10, 28310.3390/v10060283. SwinneyD. C.Phenotypic"/>
 <result pre="HoD. D.; YuenK. Y.Identification of novel small-molecule inhibitors of severe" exact="acute" post="respiratory syndrome-associated coronavirus by chemical genetics. Chem. Biol.2004, 11,"/>
 <result pre="D.; YuenK. Y.Identification of novel small-molecule inhibitors of severe acute" exact="respiratory" post="syndrome-associated coronavirus by chemical genetics. Chem. Biol.2004, 11, 1293â€&quot;1299."/>
 <result pre="BishtH.; RobertsA.; VogelL.; BukreyevA.; CollinsP. L.; MurphyB. R.; SubbaraoK.; MossB.Severe" exact="acute" post="respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia"/>
 <result pre="RobertsA.; VogelL.; BukreyevA.; CollinsP. L.; MurphyB. R.; SubbaraoK.; MossB.Severe acute" exact="respiratory" post="syndrome coronavirus spike protein expressed by attenuated vaccinia virus"/>
 <result pre="VogelL.; BukreyevA.; CollinsP. L.; MurphyB. R.; SubbaraoK.; MossB.Severe acute respiratory" exact="syndrome" post="coronavirus spike protein expressed by attenuated vaccinia virus protectively"/>
 <result pre="MossB.Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated" exact="vaccinia" post="virus protectively immunizes mice. Proc. Natl. Acad. Sci. U."/>
 <result pre="YuJ.; GaoH.; TuX.; GettieA.; FarzanM.; YuenK. Y.; HoD. D.Recombinant modified" exact="vaccinia" post="virus ankara expressing the spike glycoprotein of severe acute"/>
 <result pre="modified vaccinia virus ankara expressing the spike glycoprotein of severe" exact="acute" post="respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting"/>
 <result pre="vaccinia virus ankara expressing the spike glycoprotein of severe acute" exact="respiratory" post="syndrome coronavirus induces protective neutralizing antibodies primarily targeting the"/>
 <result pre="virus ankara expressing the spike glycoprotein of severe acute respiratory" exact="syndrome" post="coronavirus induces protective neutralizing antibodies primarily targeting the receptor"/>
 <result pre="effects of convalescent plasma therapy for patients with Middle East" exact="respiratory" post="syndrome coronavirus infection: a study protocol. SpringerPlus2015, 4, 70910.1186/s40064-015-1490-9.26618098"/>
 <result pre="of convalescent plasma therapy for patients with Middle East respiratory" exact="syndrome" post="coronavirus infection: a study protocol. SpringerPlus2015, 4, 70910.1186/s40064-015-1490-9.26618098"/>
</results>
